Drug Trial Radar · NCT01462422
Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India
Last checked: Nov 20, 2026Latest source record: Jun 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,032
Actual
Start
Dec 2011
Primary completion
Mar 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- Gynuity Health ProjectsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sri B. M. Patil Medical College, Bijapur, Karnataka, India; Jawaharlal Nehru Medical College; University of Illinois Chicago; University of California, San Francisco
- First posted
- Oct 31, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- Who can join
- Female only, from 15 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study compares two community-level strategies: selective administration of 800 mcg sublingual misoprostol to women at 350 mL blood loss for secondary prevention of postpartum hemorrhage (PPH) with universal use of 600 mcg oral misoprostol at the time of delivery for primary prevention of PPH. The study hypothesizes that at community-level births, secondary prevention for women is non-inferior (based on clinical parameters) to universal prophylaxis provided to women for primary prevention of PPH. This cluster-design non-inferiority trial has the potential to inform service delivery programs on clinical outcomes, program feasibility, cost and acceptability of two different community models of PPH care using misoprostol.
Conditions
- Postpartum Hemorrhage
Interventions
MisoprostolDrug
Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
MisoprostolDrug
Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of women with post-delivery hemoglobin ≤ 7.8 gm/dLTime frame: 72 hours (plus or minus 8 hours) after delivery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Deliveries at health sub-centers and homes
Vijayapura, Karnataka, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.